ReviewBreast cancer (Dove Medical Press)2015
Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer.
Review in Breast cancer (Dove Medical Press), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review.Technology in cancer research & treatmentPooled it
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia.Journal of health economics and outcomes research · 2026Article
- Maintenance therapy in hormone receptor-positive and human epidermal growth factor receptor 2-positive metastatic breast cancer: a real-world multicenter retrospective study.Frontiers in oncology · 2025Article
- GLDC mitigated by miR-30e regulates cell proliferation and tumor immune infiltration in TNBC.Frontiers in immunology · 2022Article
- Article
- Enhanced chemotherapeutic efficacy of the low-dose doxorubicin in breast cancer via nanoparticle delivery system crosslinked hyaluronic acid.Drug delivery · 2019Article
- Article
- Metastatic breast cancer: The Odyssey of personalization.Molecular oncology · 2016Review
- Neoadjuvant Chemotherapy Response in Breast Cancer among Nigerian Women: A Systematic Review and Meta-Analysis (2000-2025).Nigerian medical journal : journal of the Nigeria Medical AssociationReview
- Targeted therapeutic options and future perspectives for HER2-positive breast cancer.Signal transduction and targeted therapyReview
- The Dual Blockade in the Neoadjuvant Setting of HER-2 Positive Early-Stage Breast Cancer.Journal of medicine and lifeReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human epidermal growth factor receptor 2 (HER2) is a tyrosine kinase transmembrane receptor that is overexpressed on the surface of 15%-20% of breast tumors and has been associated with poor prognosis. Consistently improved pathologic response and survival rates have been demonstrated with use of trastuzumab in combination with standard chemotherapy in both early and advanced breast cancer. However, resistance to trastuzumab may pose a major problem in the effective treatment of HER2-positive breast cancer. Dual HER2 blockade, using agents that work in a complimentary fashion to trastuzumab, has more recently been explored to evade resistance in both the preoperative (neoadjuvant) and adjuvant settings. Increased effectiveness of dual anti-HER2 agents over single blockade has been recently reported in clinical studies. Pertuzumab in combination with trastuzumab and taxane is currently approved in the metastatic and neoadjuvant treatment of HER2-positive breast cancer. Various biomarkers have also been investigated to identify subsets of patients with HER2-positive tumors who would likely respond best to these targeted therapy combinations. In this article, available trial data regarding efficacy and toxicity of treatment with combination HER2 agents in the neoadjuvant and adjuvant setting have been reviewed, and relevant correlative biomarker data from these trials have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.